A Compassionate Use Study of Leronlimab in Breast Cancer
- Sponsor
- CytoDyn, Inc.
- Study ID
- NCT04313075
- Status
- No Longer Available
Conditions
- Metastatic Triple-Negative Breast Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Leronlimab — DRUGLeronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Study Details
This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC.
Key Dates
- Status verified
- Jul 2025
Related Studies
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerPHASE2 · Recruiting · National Cancer Institute (NCI) · Orange, California
- Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast CancerPHASE2 · Recruiting · Roswell Park Cancer Institute · Tampa, Florida
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Mayo Clinic · Jacksonville, Florida
- Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast CancerPHASE1/PHASE2 · Recruiting · Yuan Yuan · Los Angeles, California